# US 2021/0330638 A1 · Nano-penetrative cannabinoid oil blends and compositions and methods of formulation thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330638 A1
- Document ID: US20210330638A1
- Status: Published application
- Kind: A1
- Application number: 17/327,234
- Filed: 2021-05-21
- Published: 2021-10-28
- Earliest claimed: 2020-02-21
- Applicants: Theragun, Inc.
- Inventors: Timothy Drennan
- Web page: https://patentgrep.com/patent/US20210330638A1

## CPC

- A61K 36/3482: {Cannabis}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/10: Dispersions; Emulsions
- A61K 31/015: carbocyclic
- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K 31/085: having an ether linkage to aromatic ring nuclear carbon
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/125: Camphor; Nuclear substituted derivatives thereof
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 36/534: Mentha (mint)
- A61K 36/61: Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
- A61P 29/02: without antiinflammatory effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to methods of formulating therapeutic oil blends comprising one or more terpenes, wherein the methods may result in blends exhibiting increased stability and bioavailability. The methods may be used to produce compositions for dermal or transdermal application useful in the treatment of, e.g., pain. Disclosed methods may also result in improved homogeneity and non-crystallization of the formulated products.

## Claims

### Claim at position 1

1-68. (canceled)

### Claim 69

A cavitated therapeutic oil blend comprising:
a) 25-75% w/w cannabinoid content; and
b) 25-75% w/w terpene content,
wherein the cavitated therapeutic oil blend has an average cannabinoid crystal size of less than 300 nm at room temperature, wherein the cavitated therapeutic oil blend comprises cavitation bubbles, and wherein weight contents are calculated based on the weight of the cavitated therapeutic oil blend.

### Claim 70 (depends on 69)

The cavitated therapeutic oil blend of claim 69, wherein the average cannabinoid crystal size remains below 300 nm for a period of at least 14 days.

### Claim 71 (depends on 69)

The cavitated therapeutic oil blend of claim 69, wherein the cavitated therapeutic oil blend is not an emulsion.

### Claim 72 (depends on 69)

The cavitated therapeutic oil blend of claim 69, wherein the cavitated therapeutic oil blend: does not comprise a water phase; or comprises less than 5% water content by weight.

### Claim 73 (depends on 69)

The cavitated therapeutic oil blend of claim 69, wherein the cavitated therapeutic oil blend does not comprise any emulsifiers, surfactants, or homogenizing agents, other than those naturally occurring in hemp oil, clove bud oil, and peppermint oil.

### Claim 74 (depends on 69)

The cavitated therapeutic oil blend of claim 69, wherein the cavitated therapeutic oil blend has an average cannabinoid crystal size of less than about 60 nm at room temperature.

### Claim 75 (depends on 69)

The cavitated therapeutic oil blend of claim 69, wherein the cannabinoid is selected from the group consisting of: cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidiol monomethylether (CBDM), cannabidiol-C4 (CBD-C4), cannabidivarinic acid (CBDVA), cannabidivarin (CBDV), cannabidiorcol (CBD-C1), delta 9 tetrayhydrocannabinol (THC), and a combination thereof.

### Claim 76 (depends on 69)

The cavitated therapeutic oil blend of claim 69, wherein the cannabinoid is cannabidiol (CBD).

### Claim 77 (depends on 69)

The cavitated therapeutic oil blend of claim 69, wherein the cavitated therapeutic oil blend comprises about 15%-40% w/w eugenol.

### Claim 78 (depends on 69)

The cavitated therapeutic oil blend of claim 69, wherein the cavitated therapeutic oil blend comprises about 5%-20% w/w menthol, 5%-20% w/w menthone, or a combination thereof.

### Claim 79 (depends on 69)

The cavitated therapeutic oil blend of claim 69, wherein the cavitated therapeutic oil blend comprises about 0.1%-10% w/w d-limonene.

### Claim 80 (depends on 69)

The cavitated therapeutic oil blend of claim 69, wherein the cavitated therapeutic oil blend comprises about 0.01%-5% w/w of a terpene selected from the list consisting of: bisabolol, borneol, caryophyllene, carene, camphene, camphor, cineol, citronellal, eucalyptol, geraniol, guaiol, humulene, isopropyltoluene, isopulegol, linalool, beta-myrcene, nerolidol, ocimene, alpha-pinene, beta-pinene, phytol, pulegone, alpha-terpinene, gamma-terpinene, terpinolene, and thymol.

### Claim 81 (depends on 69)

The cavitated therapeutic oil blend of claim 69, wherein the terpene content comprises an essential oil.

### Claim 82 (depends on 81)

The cavitated therapeutic oil blend of claim 81, wherein the essential oil comprises clove bud oil or peppermint oil.

### Claim 83 (depends on 69)

The cavitated therapeutic oil blend of claim 69, wherein the cavitated therapeutic oil blend comprises about 15-40% w/w clove bud oil.

### Claim 84 (depends on 69)

The cavitated therapeutic oil blend of claim 69, wherein the cavitated therapeutic oil blend comprises about 5-20% w/w peppermint oil.

### Claim 85 (depends on 69)

The cavitated therapeutic oil blend of claim 69, wherein the cavitated therapeutic oil blend has increased topical absorption as compared to either:
a) a control un-cavitated formulation comprising all ingredients of the therapeutic oil blend, but no cavitation bubbles or;
b) a control cavitated formulation without the terpene content.

### Claim 86 (depends on 69)

The cavitated therapeutic oil blend of claim 69, wherein the cavitated therapeutic oil blend has increased anesthetic, analgesic, and/or vasodilatory properties as compared to either:
a) a control un-cavitated formulation comprising all ingredients of the therapeutic oil blend, but no cavitation bubbles or;
b) a control cavitated formulation without the terpene content.

### Claim 87 (depends on 69)

The cavitated therapeutic oil blend of claim 69, wherein the cavitated therapeutic oil blend cavitation was induced through mechanical agitation.

### Claim 88 (depends on 87)

The cavitated therapeutic oil blend of claim 87, wherein the mechanical agitation comprises sonication.

### Claim 89

A cavitated therapeutic oil blend that comprises:
a) 25-90% w/w cannabidiol content;
b) 25%-75% w/w terpene content, wherein the terpene content comprises:
i) clove bud oil;
ii) peppermint oil; or
iii) both i) and ii),
wherein the cavitated therapeutic oil blend has an average cannabinoid crystal size of less than 300 nm at room temperature, wherein the cavitated therapeutic oil blend comprises cavitation bubbles, and wherein weight contents are calculated based on the weight of the cavitated therapeutic oil blend.

### Claim 90 (depends on 69)

A topical formulation comprising the therapeutic oil blend of claim 69, said topical formulation selected from the group consisting of: a lotion, a body balm, a salve, a massage oil, a topical gel, a moisturizer, and a cream.

### Claim 91 (depends on 69)

An ingestible formulation comprising the therapeutic oil blend of claim 69, said ingestible formulation selected from the group consisting of: a tablet, a pressed tablet, a tincture, and a drink mix.

### Claim 92

A method of preparing a cavitated therapeutic oil blend, the method comprising:
a) heating a cannabinoid under conditions sufficient to melt or dissolve the cannabinoid, thereby producing a liquid cannabinoid;
b) admixing:
i) 25-75% w/w liquid cannabinoid; and
ii) 25-75% w/w terpene, thereby producing a mixture; and
c) cavitating the mixture of step (b) under conditions sufficient to generate cavitation bubbles, thereby generating the cavitated therapeutic oil blend, wherein the cavitated therapeutic oil blend has an average cannabinoid crystal size of less than 300 nm at room temperature, and wherein weight contents are calculated based on the weight of the cavitated therapeutic oil blend.

### Claim 93 (depends on 92)

The method of claim 92, wherein the mixture is kept below a temperature of about 60° C. during step (c).